Profusa, Inc., a South San Francisco, CA-based developer of biologically integrated sensors that allow individuals to monitor their unique body chemistry, secured $13.2m in Series B financing.
The round was led by 3E Bioventures, with participation from Asset Management Ventures, Qihoo 360, and other Series A investors. In conjunction with the funding, Karen Liu, Ph.D., Managing Partner of 3E Bioventures, joined Profusa’s board along with Joan Braddi, Vice President of Global Product Partnerships at Google, Inc., a subsidiary of Alphabet Inc.
The company intends to use the funds for the development and commercialization of its technology.
Founded in 2009 and led by Ben Hwang, Ph.D., chairman and CEO, Profusa provides an internal biosensor technology for long-term, continuous monitoring of body chemistry for improving personal health and managing disease. The company’s first product, the Lumee Oxygen Sensing System™, is slated to be available in Europe in early 2016 for the measurement of tissue-oxygen perfusion in the clinical management of chronic wounds.
Profusa has raised more than $30m in funding since its creation.